Raymond Valérie-Ann, Selliah Subajini, Ethier Chantal, Houle Robert, Jouan Loubna, Maniere Thibaut, Lamarre Daniel, Willems Bernard, Bilodeau Marc
Laboratoire d'hépatologie cellulaire, Centre hospitalier de l'Université de Montréal (CHUM)-Hôpital Saint-Luc, Montréal, QC, Canada.
Liver Int. 2009 Jul;29(6):942-9. doi: 10.1111/j.1478-3231.2009.01996.x. Epub 2009 Mar 3.
BACKGROUND/AIM: Since the discovery of hepatitis C virus (HCV), researchers have encountered difficulties with in vitro models. The aim of this study was to determine whether HCV-infected human primary hepatocytes, isolated from cirrhotic livers at liver transplantation, can be used as a model to study HCV infection.
Hepatocytes were isolated with collagenase and cultured over a 20-day period on different matrices. Viral kinetics was monitored with/without treatment by real-time polymerase chain reaction.
Cell yield and viability were higher with uninfected/non-cirrhotic livers (77.2+/-1.8%) in comparison with HCV-infected cirrhotic livers (68.8+/-12%). HCV-infected hepatocytes behaved similar to non-infected cells and expressed albumin and cytochrome P4502E1. HCV-positive strand was identified in supernatants and cell lysates. HCV-negative strand was only found inside cells and correlated with viral RNA recovery in the medium. Improvement in the degree of hepatocyte differentiation was associated with better HCV recovery. Antiviral treatment with interferon-alpha, EX4 and cyclosporine A induced significant reductions in HCV RNA.
Primary cultures of HCV-infected human hepatocytes from end-stage cirrhotic livers is feasible, represents an excellent model to study specific virus-host interactions and can be used to assess viral replication.
背景/目的:自丙型肝炎病毒(HCV)被发现以来,研究人员在体外模型方面遇到了困难。本研究的目的是确定从肝移植时的肝硬化肝脏中分离出的HCV感染的人原代肝细胞是否可作为研究HCV感染的模型。
用胶原酶分离肝细胞,并在不同基质上培养20天。通过实时聚合酶链反应监测有无治疗情况下的病毒动力学。
与HCV感染的肝硬化肝脏(68.8±12%)相比,未感染/非肝硬化肝脏的细胞产量和活力更高(77.2±1.8%)。HCV感染的肝细胞表现与未感染细胞相似,表达白蛋白和细胞色素P4502E1。在上清液和细胞裂解物中鉴定出HCV正链。HCV负链仅在细胞内发现,并与培养基中的病毒RNA回收相关。肝细胞分化程度的改善与更好的HCV回收相关。用α干扰素、EX4和环孢素A进行抗病毒治疗可显著降低HCV RNA。
来自终末期肝硬化肝脏的HCV感染的人肝细胞原代培养是可行的,是研究特定病毒-宿主相互作用的优秀模型,可用于评估病毒复制。